SAB Biotherapeutics (SABS) Operating Expenses (2020 - 2026)

SAB Biotherapeutics' Operating Expenses history runs 7 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• Quarterly Operating Expenses rose 85.64% year-over-year to $20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.2 million (up 36.35% YoY) and the FY2025 annual result came in at $49.0 million, up 10.67% from the prior year.
• Operating Expenses was $20.0 million for Q1 2026 at SAB Biotherapeutics, up from $15.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $20.0 million in Q1 2026 and bottomed at $6.6 million in Q2 2023.
• A 5-year average of $12.1 million and a median of $11.3 million in 2024 frame the typical range for Operating Expenses.
• Peak annual rise in Operating Expenses reached 91.39% in 2023, while the deepest fall reached 56.87% in 2023.
• SAB Biotherapeutics' Operating Expenses stood at $10.0 million in 2022, then soared by 91.39% to $19.2 million in 2023, then tumbled by 47.21% to $10.1 million in 2024, then soared by 55.78% to $15.8 million in 2025, then grew by 26.81% to $20.0 million in 2026.
• Business Quant data shows SABS's Operating Expenses at $20.0 million in Q1 2026, $15.8 million in Q4 2025, and $12.7 million in Q3 2025.